4//SEC Filing
Allan Jonathan 4
Accession 0001966716-25-000008
CIK 0001623526other
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 8:49 PM ET
Size
16.6 KB
Accession
0001966716-25-000008
Insider Transaction Report
Form 4
Allan Jonathan
GENERAL COUNSEL & CORP SEC
Transactions
- Exercise/Conversion
Common Stock
2025-12-03+6,000→ 25,612 total - Sale
Common Stock
2025-12-04$30.76/sh−824$25,349→ 24,788 total - Sale
Common Stock
2025-12-04$31.32/sh−194$6,075→ 24,594 total - Sale
Common Stock
2025-12-05$31.33/sh−1,004$31,456→ 23,590 total - Sale
Common Stock
2025-12-05$31.08/sh−5,437$168,997→ 18,153 total - Sale
Common Stock
2025-12-05$31.76/sh−2,344$74,445→ 15,809 total - Exercise/Conversion
Performance Stock Units
2025-12-03−6,000→ 0 totalExp: 2025-12-03→ Common Stock (6,000 underlying)
Footnotes (9)
- [F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
- [F5]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.59 to $31.97 per share, inclusive.
- [F8]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F9]Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001966716
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 8:49 PM ET
- Size
- 16.6 KB